Clinical and Treatment Management Decisions in Two Asymptomatic Late-Onset Pompe Disease Siblings – Further Evidence of Scoliosis as a Clinical Sentinel Sign for Juvenile Pompe Disease

Juan C. Llerena Jr1,2,*, Ana Carolina Esposito1, Anneliese Barth1, Daniel Souza e Silva1, Nicollete Cavalcânti1, Bruna Sixel1, Tatiana Magalhães1, Fernanda Scalco1, Maria Lúcia Oliveira1, Anna Patrícia Riello4 and Dafne Horotviz1
1Centro de Genética Médica, Instituto Nacional Fernandes Figueira, Fiocruz, Rio de Janeiro, Brazil
2Faculdades Arthur Sá Earp (FASE), Faculdade de Medicina, Petrópolis, Rio de Janeiro, Brazil
3LABEIM (Laboratório de Erros Inatos do Metabolismo), Instituto de Química, Departamento de Bioquímica, UFRJ, Rio de Janeiro, Brazil
4Lab’s D’Or, Rio de Janeiro, Brazil

An asymptomatic 17-year-old long-term Pompe disease patient was identified by chance through his dermatologist due to partial alopecia. Through high CK (1,310 IU/L) and muscle/hepatic biomarkers (AST, 162 IU/L; ALT, 189 IU/L) a muscle biopsy was performed revealing vacuolated muscle pathology with H-E and PAS stains. A compound heterozygote pathogenic GAA genotype was detected (-32-13 T>G/c.2560C>T). A series of clinical and laboratory evaluations identified several abnormal clinical signs, despite the absence of clinical symptoms. As the patient had a positive DBS, diminished GAA activity in leukocytes (0.56 nmol/h/mg protein – RV: 1.0–5.9), high urinary Glc4 levels on HPLC, abnormal FVC drop during sitting–supine transition (>14%), and abnormalities on his tongue and edema of his thighs, seen on MRI, the decision was taken to initiate enzymatic replacement therapy (ERT) with 20 mg/kg rhGAA (Myozyme®), even though no subjective clinical symptoms were present. After 4 years on ERT treatment and motor/respiratory rehabilitation programs, all clinical parameters worsened, especially CK levels, muscle MRI with an overall muscle substitution for fat with muscle mass volume reduction; and a higher FVC drop during sitting–supine transition (>18%) were noted. Based on these clinical and laboratory evaluations, Myozyme® dosing off-label increase (40 mg/kg) for ERT was considered.

The patient’s asymptomatic 12-year-old sister revealed a similar GAA compound heterozygote genotype (-32-13 T>G/c.2560C>T), positive DBS and low GAA leukocyte activity (0.40 nmol/h/mg protein). Clinical follow-up with serial serum CK, urinary Glc4 biomarker, pulmonary functional evaluations, motor and muscle functional and strength tests, muscle MRI and ENM were unremarkable. After 4 years of clinical follow-up, the physiotherapist observed an abnormal posture of the patient and an important scoliosis was diagnosed. An ENM of the paraspinal and sternocleidomastoid muscles revealed sporadic myotonic discharges. A new series of clinical and laboratory evaluations was performed and all evaluations were normal, including serum CK, muscle MRI, and pulmonary FVC sitting–supine evaluation. The decision to start Myozyme® ERT treatment was not a consensus among the clinical team. Scoliosis has been registered in few cases as a clinical complication in Pompe disease1, and may serve as a clinical alert for screening for Pompe disease among the “idiopathic” juvenile scoliosis group.

REFERENCE